Johnson & Johnson Advances Cancer Treatment Through Halda Therapeutics Acquisition

Johnson & Johnson has completed the acquisition of Halda Therapeutics, bringing a novel targeted therapy platform into its oncology portfolio with the aim of addressing persistent challenges in cancer treatment, particularly treatment resistance in solid tumors.

The transaction adds both a clinical-stage prostate cancer therapy and a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform, expanding Johnson & Johnson’s ability to develop oral, precision-targeted therapies designed to selectively eliminate tumor cells.

Addressing resistance in prostate cancer
A central element of the acquisition is HLD-0915, a once-daily oral therapy currently in clinical development for prostate cancer. Resistance to existing treatments remains a major limitation in advanced prostate cancer, often leading to disease progression despite multiple lines of therapy.

HLD-0915 is designed to overcome key resistance pathways by enabling targeted tumor cell eradication through a differentiated mechanism of action. By focusing on precision targeting rather than broad cytotoxic effects, the therapy aims to improve durability of response while limiting impact on healthy tissue.

RIPTAC™ platform and therapeutic approach
Halda’s RIPTAC™ platform is designed to induce proximity between specific intracellular targets, triggering selective cancer cell killing. This approach expands the range of molecular targets that can be addressed with oral therapies, including targets that are difficult to modulate using conventional small molecules.

In addition to the prostate cancer program, the platform supports earlier-stage candidates in breast cancer, lung cancer, and other solid tumors. The technology may also enable the development of targeted therapies beyond oncology, depending on future research outcomes.

Integration into oncology research and development
With the acquisition completed, Johnson & Johnson plans to advance Halda’s existing clinical and preclinical programs while applying the RIPTAC™ platform across its broader oncology research efforts. The addition of the platform complements the company’s existing focus on mechanism-driven cancer therapies and precision medicine.

From an operational perspective, the acquisition is expected to strengthen Johnson & Johnson’s ability to translate novel targeting strategies into scalable drug development programs, particularly in areas where current treatments face biological resistance.

Financial and development considerations
The acquisition was completed for $3.05 billion in cash and will be accounted for as a business combination. Johnson & Johnson expects earnings dilution in the fourth quarter of 2025 and in 2026, with an estimated total adjusted earnings-per-share impact of approximately $0.20, split evenly between the two years. Further financial guidance is expected during the company’s fourth-quarter earnings call in January 2026.

Implications for future cancer treatment
While the acquisition represents a strategic expansion of Johnson & Johnson’s oncology pipeline, its longer-term significance will depend on clinical outcomes. If successful, RIPTAC™-based therapies could contribute to a new generation of oral, targeted cancer treatments capable of addressing resistance mechanisms that limit current standards of care.

By integrating a differentiated targeting platform with its existing oncology capabilities, Johnson & Johnson aims to advance cancer treatment approaches that prioritize precision, durability, and patient-focused therapeutic design.

www.jnj.com